DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/d2tql8/oral_mucositis) has announced the addition of the "Oral Mucositis - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Oral Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oral Mucositis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Aldeyra Therapeutics, Inc.
- Cellceutix Corporation
- Clevexel Pharma SAS
- Colby Pharmaceutical Company
- Daewoong Pharmaceutical Co., Ltd.
- Intrexon Corporation
- Laila Pharmaceuticals Pvt. Ltd.
- Onxeo SA
- Otsuka Holdings Co., Ltd.
- ProCertus BioPharm Inc.
- Soligenix, Inc.
- Spectrum Pharmaceuticals, Inc.
- Sucampo Pharmaceuticals, Inc.
Drug Profiles
- AG-013
- AP-001
- AP-002
- brilacidin tetrahydrochloride
- clonidine hydrochloride ER
- cobiprostone
- CVXL-0095
- dusquetide
- GC-4403
- GC-4419
- Gene Therapy for Oral Mucositis
- JVRSOD
- LP-00409
- nepidermin
- NS-2
- OralX
- pralatrexate
- rebamipide
- Regenasyn
For more information visit http://www.researchandmarkets.com/research/d2tql8/oral_mucositis
